Viracept
Product Images NDC 53808-0809

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Viracept (NDC 53808-0809). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image For 625 mg (Viracept 625mg (agouron))

Label Image For 625 mg (Viracept 625mg (agouron))
VIRACEPT is a prescription medication available in the form of 625mg tablets. The package contains 30 tablets manufactured by Agouron. The lot number for Agouron is 0734069 and the lot number for DOH is 111320083. The medication expires on 053110 and has been packaged by DOH Central Pharmacy in Tallahassee, FL 32304. The code IR WO and the string 6301C027703 are also present but their meaning is unclear.*
FDA Label Image

Chemical Structure (Viracept 01)

Chemical Structure (Viracept 01)
FDA Label Image

Figure 1 (Viracept 02)

Figure 1 (Viracept 02)
This is a figure showing the results of a study (Study S11) on the percentage of patients with HIV RNA below 400 copies/mL. The study compares three different treatments: VIRACEPT 750 mg + ZDVTC (n=39), VIRACEPT 500 mg + ZDVITC (n=97), and placebo + ZDVISTC (n=101). The x-axis shows the study week and the y-axis shows the percentage of patients with HIV RNA below 400 copies/mL.*
FDA Label Image

Figure 2 (Viracept 03)

Figure 2 (Viracept 03)
The text is describing a figure labeled "Figure 2" and showing the mean change from baseline in CD cell counts for a study labeled "S11". The figure compares the mean change in CD cell count for different treatments, including VIRACEPT 750mg + ZDV/ATC, VIRACEPT 500mg + ZDV/TC, and placebo + ZDVI/ATC. The study week is also indicated. However, without the context of the actual figure, it is difficult to provide further details or insights.*
FDA Label Image

Figure 3 (Viracept 04)

Figure 3 (Viracept 04)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.